La guía definitiva sobre edición genética.
Menú
Inicio Aprender Noticias Pregunta al Atlas
Explorar Tecnologías Enfermedades Tratamientos Ensayos clínicos Empresas Científicos Genes Investigación Instituciones
Más allá de la medicina Agricultura Ética Inversión Mapa mundial
Aprender y herramientas Empieza aquí Glosario A–Z Comparar tecnologías Cronología Listas y rankings Agentes de IA ★ Guardado API
Acerca de Quiénes somos Metodología Fuentes de datos Política editorial Contacto Avisos legales

🧭 Vista guiada
¿Eres nuevo en genética? Explicamos cada término mientras navegas, en un lenguaje sencillo. Las mismas páginas, con la ayuda incorporada.

⚡ Opinión experta
Ya conoces la biología. Solo el contenido — limpio y compacto, sin explicaciones adicionales. Esta es la vista predeterminada.

Idioma de la interfaz
Modo claro

Technology · RNA targeting

RNA Interference

Uses the cell's own machinery to destroy a specific RNA message, lowering a protein's level without touching DNA.

Approved RNAreversibleapproved
Approved treatment At least one medicine using this approach has been authorised by a national regulator for this use.

Explicación sencilla

Cells have a built-in system for shredding RNA messages they recognise as unwanted. RNA interference feeds that system a short piece of RNA matching the gene you want quietened, and the cell destroys those messages for you. It is temporary — repeat dosing is required — and it is not gene editing at all, but it is the closest comparison for many of the same diseases, and it has approved medicines.

Profundizar

Small interfering RNAs are loaded into the RNA-induced silencing complex, where the guide strand directs Argonaute-mediated cleavage of complementary mRNA. GalNAc conjugation gives efficient hepatocyte uptake, making the liver the dominant target tissue. Approved siRNA medicines exist for several conditions, including hereditary transthyretin amyloidosis — where they compete directly with in vivo CRISPR programmes aimed at the same gene.

The honest comparison with gene editing

For ATTR amyloidosis, the same target gene — TTR — is addressed by approved RNAi medicines given repeatedly and by an investigational one-time CRISPR knockout. The editing approach offers a single administration; the RNAi approach offers years of accumulated safety data and the ability to stop. Neither answer is obviously right, and it is the clearest example on this site of why 'newer' does not settle a clinical question.

The honest comparison with gene editing
A silencing complex loaded with a short guide, cutting a matching transcript. Illustration generated for The CRISPR Atlas — a visual aid, not a photograph or a literal depiction of molecular structure.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

RNA Editing

Diseases

ATTR Amyloidosis
Solo información educativa Esta página es una referencia, no asesoramiento médico. El estado de la investigación y la situación regulatoria cambian; comprueba la fecha de última actualización que aparece arriba y confirma cualquier dato importante con las fuentes primarias indicadas.